Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US
Firms Receive First FDA Approval For Higher-Strength 100mg/ml Humira Biosimilar
• By David Wallace
Samsung Bioepis and Organon are the first to have both a high- and low-concentration adalimumab biosimilar approved in the US • Source: Shutterstock 
